HIGHTIDE

HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

BUSINESS UPDATE
ENTERING INTO THE FRAMEWORK AGREEMENT WITH SSY GROUP

The board (the "**Board**") of directors (the "**Directors**") of HighTide Therapeutics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that a wholly-owned subsidiary of the Group has entered into a strategic co-operation framework agreement (the "**Framework Agreement**") with Shijiazhuang No. 4 Pharmaceutical Co., Ltd. (石家莊四藥有限公司) ("**Shijiazhuang No. 4 Pharmaceutical**"), a wholly-owned subsidiary of SSY Group Limited ("**SSY Group**", a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2005)), with the aim of integrating the Group's unique advantages in the sector of multi-systematic synergistic innovation of natural products and SSY Group's extensive experience in the areas of, among others, activity screening, formulation development, outcome conversion, quality and cost control, to jointly tackle the difficulties in the industry, thereby providing ground-breaking solutions for the sectors of metabolic chronic disease, longevity and anti-aging worldwide.

THE FRAMEWORK AGREEMENT

Pursuant to the Framework Agreement and in accordance with the terms and conditions therein, the Group and SSY Group (the "**Parties**") will leverage on their respective strengths to jointly research and develop for the sectors of metabolic chronic diseases, longevity and anti-aging worldwide, and implement the entire work chain of the co-operation project, including, among others, outcome conversion, application for marketing approval and market promotion, which encompasses the establishment of a joint research center, the research and development of innovative products, the development of an industry ecosystem, as well as the execution of market promotion and commercialization.

The Framework Agreement only provides a framework for the strategic co-operation between the Parties, and specific co-operation agreements (if any) will be entered into separately by the Parties or by entities designated by them upon negotiation between the Parties.

INFORMATION ON SSY GROUP AND SHIJIAZHUANG NO. 4 PHARMACEUTICAL

SSY Group is a company incorporated under the laws of the Cayman Islands with limited liability, the shares of which are listed on The Stock Exchange of Hong Kong Limited (stock code: 2005). SSY Group is principally engaged in the research, development, manufacturing and sales of pharmaceutical products, which includes finished medicines, bulk pharmaceuticals and medical materials. Shijiazhuang No. 4 Pharmaceutical is a wholly-owned subsidiary of SSY Group.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, Shijiazhuang No. 4 Pharmaceutical, SSY Group and their respective ultimate beneficial owners are third parties independent of and not connected with the Company and its connected persons. The Framework Agreement and the transactions thereunder do not constitute any notifiable transaction or connected transaction of the Company under Chapters 14 and 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

This announcement is made by the Company on a voluntary basis to keep the shareholders and potential investors of the Company informed of the business update of the Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. The Company will make further announcement in relation to the Framework Agreement in accordance with the Listing Rules as and when appropriate.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, December 19, 2024

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. Jin LI and Mr. HUNG Tak Wai as independent non-executive Directors.